[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia


Description

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.This is a single-institution Phase I pilot study designed to test the safety and tolerability of combining venetoclax with Vyxeos (CPX-351, cytarabine and daunorubicin liposome) for the treatment of relapsed/refractory acute leukemia in young patients. Subjects will receive a single course of study therapy consisting of daily, oral venetoclax at an assigned dose level with a 3-day ramp-up to target dose and Vyxeos administered intravenously at the established dose on Days 1, 3, and 5. In addition to safety and tolerability, the overall response rate to these therapies will be estimated. Pharmacokinetic (PK) analysis will also be conducted to define the drug clearance of venetoclax in this combination.

Trial Eligibility

Inclusion Criteria: * Ages 1-39 years * Diagnosis of one of the following: * Acute myeloid leukemia (AML) * Acute undifferentiated leukemia (AUL) * Mixed phenotype acute leukemia (MPAL) * T-cell acute lymphoblastic leukemia (T ALL) * Early thymocyte precursor (ETP) ALL * KMT2A-rearranged ALL * Disease status * Relapsed/Refractory AML, MPAL and AUL * Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETP ALL * Karnofsky/ Lanksy performance level score of greater than or equal to 50 percent * Prior therapy requirements * Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT) or Anthracycline Exposure * 14 days must have elapsed since the completion of systemic cytotoxic therapy other than hydroxyurea, decitabine or azacitidine * 2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least 6 weeks must have elapsed if other substantial bone marrow radiation * Adequate renal, liver, cardiac and central nervous system (CNS) function Exclusion Criteria: * Diagnosis of one of the following: * Acute Promyelocytic Leukemia (APML) * Acute leukemia with CNS status 3 involvement * Philadelphia chromosome positive leukemia (Ph+ ALL, MPAL, or AUL) * Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure syndrome or DNA repair disorder * Wilson's Disease or other copper-metabolism disorder * Pregnant or breastfeeding * Uncontrolled infection * Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum * Unable to swallow tablets * Receipt of growth factors within 7 days prior to enrollment * Currently receiving another investigational drug * Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents or hydroxyurea) * Unable to comply with the safety monitoring requirements of the study

Study Info

Organization

Children's Hospital Medical Center, Cincinnati


Primary Outcome

Feasibility of combining venetoclax and Vyxeos (dose limiting toxicities)


Outcome Timeframe 28 days

NCTID NCT03826992

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2018-12-27

Completion Date 2025-01

Enrollment Target 21

Interventions

DRUG Vyxeos

DRUG Venetoclax

Locations Recruiting

Cincinnati Children's Hospital Medical Center

United States, Ohio, Cincinnati


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Acute Myeloid Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Abbvie
Astellas Pharma
Servier

Follow Us

facebook instagram youtube